Key result
Sodium-glucose cotransporter 2 inhibitors may provide dual benefits as both hypoglycemic agents and epicardial adiposity normalizing agents, potentially decreasing cardiac risk in diabetic patients.
Why the study?
Pathologic epicardial adipose tissue impairs heart function, and emerging reports suggest SGLT2 inhibitors may modulate epicardial adiposity to reduce cardiac complications in diabetic patients.
Do SGLT2 inhibitors modulate epicardial adiposity and decrease the risk of cardiac complications in diabetic patients?
Do SGLT2 inhibitors modulate epicardial adiposity and decrease the risk of cardiac complications in diabetic patients?
SGLT2 inhibitors may offer cardioprotective benefits in diabetic patients by modulating epicardial adiposity.
Answers are grounded in this paper and cite their sources.
May support SGLT2 inhibitor consideration for cardiac risk reduction in diabetes; leaves open confirmation of epicardial effects in prospective trials.
Epicardial adipose tissue is a layer of adipocytes that physiologically surround the myocardium and play some physiologic roles in normal heart function. However, in pathologic conditions, the epicardial adipose tissue can present a potent cardiac risk factor that is capable of impairing heart function through several pathways, increasing the risk of dysrhythmia and creating an inflammatory milieu around the heart tissues. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) are a relatively newly introduced class of antidiabetes drugs which effectively normalize blood glucose via overt glycosuria. Some recent reports suggest that these drugs are able to modulate epicardial adiposity and decrease the risk of cardiac complications in diabetic patients who are at higher risk of epicardial adiposity-dependent cardiac disorders. If proven to be true, these antidiabetic drugs can provide dual benefits as both hypoglycemic agents and as epicardial adiposity normalizing agents, thus providing cardiac benefits. In this study, we discuss the physiological and pathophysiological importance of epicardial adiposity and the potential positive effects of SGLT2is in the diabetic milieu.
No takes yet. Share an insight, caveat, or question.
Yaribeygi et al. (2022) conducted a review in Diabetes and epicardial adiposity. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) was evaluated. Sodium-glucose cotransporter 2 inhibitors may provide dual benefits as both hypoglycemic agents and epicardial adiposity normalizing agents, potentially decreasing cardiac risk in diabetic patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: